Ron Bradford Selected Research

Allergens

1/2019	Alcaftadine 0.25% versus Olopatadine 0.1% in Preventing Cedar Pollen Allergic Conjunctivitis in Japan: A Randomized Study.
1/2004	Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ron Bradford Research Topics

Disease

2	Hyperemia 01/2019 - 01/2004
2	Allergic Conjunctivitis (Giant Papillary Conjunctivitis) 01/2019 - 01/2004
2	Pruritus (Itching) 01/2019 - 01/2004
1	Conjunctivitis 01/2019

Drug/Important Bio-Agent (IBA)

2	AllergensIBA 01/2019 - 01/2004
1	alcaftadine FDA Link 01/2019
1	Olopatadine Hydrochloride (Patanol)FDA Link 01/2019
1	Ophthalmic Solutions (Eye Drops)IBA 01/2019
1	epinastine FDA Link 01/2004
1	levocabastine (Bilina)FDA Link 01/2004